Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc. (Burnaby, Canada) develops targeted neurology drugs, leading with Azetukalner— a Phase III Kv7 potassium channel opener for epilepsy and mood disorders. It also partners with Neurocrine on Phase I NBI‑921352 and other CNS candidates.
Headquarters: United States (USA)
- Website: Visit Site 🔗
- Type: Corporation
Company Profile
- Sector: Professional Services
- Industry: Biotechnology Research
- Employees: 316
- HQ: Burnaby
Unlock the full potential.
Upgrade
Get access to Relative P/E Ratio Valuation Histogram.